Free tool
Stocks listed on Nasdaq GS
We cover 89 companies listed on Nasdaq GS. The median market value in the group is $3.22B. Across the group, the median move over the past trading day is −0.36%. 75% of the 84 with a 200-day average trade above it. Price change over the past year runs from −38.8% to +284.1% across the middle 80 percent of the group, with a median of +50.2%. Across the group, 1 company currently carries a tier A volume signal.
Other lists in this group
Table
89 of 1,279 companies match these filters.Clear filters
| Ticker | Company | Market cap (USD) | Size | 1Y return | Next report |
|---|---|---|---|---|---|
| PODD | Insulet Corporation | $9.94B | Mid cap | −57.12% | Nov 5, 2026 |
| TWST | Twist Bioscience Corporation | $9.41B | Mid cap | +451.89% | Nov 16, 2026 |
| PCVX | Vaxcyte, Inc. | $9.09B | Mid cap | +99.97% | Nov 3, 2026 |
| IMVT | Immunovant, Inc. | $9.07B | Mid cap | +189.13% | Nov 9, 2026 |
| CRNX | Crinetics Pharmaceuticals, Inc. | $9.00B | Mid cap | +179.08% | Nov 5, 2026 |
| HQY | HealthEquity, Inc. | $8.75B | Mid cap | +18.69% | Aug 27, 2026 |
| BRKR | Bruker Corporation | $8.69B | Mid cap | +70.56% | Nov 3, 2026 |
| TXG | 10x Genomics, Inc. | $8.37B | Mid cap | +358.35% | Nov 5, 2026 |
| ALKS | Alkermes plc | $8.25B | Mid cap | +68.07% | Oct 28, 2026 |
| SYRE | Spyre Therapeutics, Inc. | $8.13B | Mid cap | +446.12% | Nov 3, 2026 |
| CAI | Caris Life Sciences, Inc. | $7.58B | Mid cap | −29.83% | Nov 4, 2026 |
| SRRK | Scholar Rock Holding Corporation | $7.31B | Mid cap | +74.18% | Nov 12, 2026 |
| CGON | CG Oncology, Inc. | $6.95B | Mid cap | +196.15% | Nov 9, 2026 |
| ERAS | Erasca, Inc. | $6.70B | Mid cap | +1112.03% | Nov 11, 2026 |
| COGT | Cogent Biosciences, Inc. | $6.39B | Mid cap | +196.85% | Nov 3, 2026 |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.27B | Mid cap | +92.20% | Oct 29, 2026 |
| PTCT | PTC Therapeutics, Inc. Common Stock | $6.07B | Mid cap | +46.02% | Nov 5, 2026 |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.05B | Mid cap | +133.47% | Oct 27, 2026 |
| DFTX | Definium Therapeutics, Inc. | $5.88B | Mid cap | +344.37% | Nov 5, 2026 |
| SHC | Sotera Health Company | $5.58B | Mid cap | +18.42% | Nov 3, 2026 |
| MMED | MiniMed Group, Inc. | $5.48B | Mid cap | +5.41% | Sep 1, 2026 |
| MMSI | Merit Medical Systems, Inc. | $5.44B | Mid cap | −0.28% | Oct 29, 2026 |
| ACAD | ACADIA Pharmaceuticals Inc. | $5.07B | Mid cap | +11.33% | Nov 4, 2026 |
| DYN | Dyne Therapeutics, Inc. | $4.92B | Mid cap | +93.26% | Nov 5, 2026 |
| EWTX | Edgewise Therapeutics, Inc. | $4.80B | Mid cap | +207.13% | Nov 5, 2026 |
| LFST | LifeStance Health Group, Inc. | $4.69B | Mid cap | +121.31% | Nov 5, 2026 |
| WAY | Waystar Holding Corp. | $4.63B | Mid cap | −34.97% | Oct 28, 2026 |
| BLLN | BillionToOne, Inc. | $4.54B | Mid cap | −11.68% | Nov 5, 2026 |
| ICUI | ICU Medical, Inc. | $4.49B | Mid cap | +41.83% | Nov 5, 2026 |
| ELVN | Enliven Therapeutics, Inc. | $4.46B | Mid cap | +194.32% | Nov 11, 2026 |
| LIVN | LivaNova PLC | $4.41B | Mid cap | +41.56% | Nov 4, 2026 |
| HTFL | Heartflow, Inc. | $4.26B | Mid cap | +40.79% | Nov 11, 2026 |
| INDV | Indivior Pharmaceuticals, Inc. | $4.23B | Mid cap | +47.06% | Nov 5, 2026 |
| ADPT | Adaptive Biotechnologies Corporation | $4.18B | Mid cap | +101.70% | Nov 4, 2026 |
| AMLX | Amylyx Pharmaceuticals, Inc. | $4.13B | Mid cap | +292.38% | Nov 5, 2026 |
| IRTC | iRhythm Holdings, Inc. | $4.06B | Mid cap | −29.83% | Nov 5, 2026 |
| LEGN | Legend Biotech Corporation | $4.02B | Mid cap | −40.44% | Nov 11, 2026 |
| IDYA | IDEAYA Biosciences, Inc. | $4.01B | Mid cap | +66.32% | Nov 9, 2026 |
| DNLI | Denali Therapeutics Inc. | $3.98B | Mid cap | +57.50% | Nov 5, 2026 |
| ABCL | AbCellera Biologics Inc. | $3.97B | Mid cap | +181.38% | Nov 5, 2026 |
| OPCH | Option Care Health, Inc. | $3.60B | Mid cap | −15.91% | Oct 29, 2026 |
| GRAL | GRAIL, Inc. | $3.55B | Mid cap | +136.66% | Nov 11, 2026 |
| QURE | uniQure N.V. | $3.53B | Mid cap | +223.49% | Nov 9, 2026 |
| MRVI | Maravai LifeSciences Holdings, Inc. | $3.30B | Mid cap | +281.97% | Nov 5, 2026 |
| MBX | MBX Biosciences, Inc. | $3.22B | Mid cap | +366.53% | Nov 5, 2026 |
| BEAM | Beam Therapeutics Inc. | $3.21B | Mid cap | +79.06% | Nov 3, 2026 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.12B | Mid cap | +60.64% | Oct 27, 2026 |
| TARS | Tarsus Pharmaceuticals, Inc. | $3.10B | Mid cap | +22.19% | Nov 4, 2026 |
| ALMS | Alumis Inc. | $3.06B | Mid cap | +380.08% | Nov 12, 2026 |
| AVAH | Aveanna Healthcare Holdings Inc. | $2.97B | Mid cap | +73.50% | Nov 5, 2026 |
| ALHC | Alignment Healthcare, Inc. | $2.88B | Mid cap | −13.88% | Oct 29, 2026 |
| ACHC | Acadia Healthcare Company, Inc. | $2.85B | Mid cap | +37.81% | Nov 4, 2026 |
| PRVA | Privia Health Group, Inc. | $2.71B | Mid cap | −3.13% | Nov 5, 2026 |
| WGS | GeneDx Holdings Corp. | $2.69B | Mid cap | −30.11% | Oct 27, 2026 |
| PGEN | Precigen, Inc. | $2.65B | Mid cap | +61.66% | Nov 12, 2026 |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.61B | Mid cap | −12.10% | Nov 3, 2026 |
| PHVS | Pharvaris N.V. | $2.60B | Mid cap | +55.59% | Nov 12, 2026 |
| NEOG | Neogen Corporation | $2.54B | Mid cap | +103.83% | Oct 8, 2026 |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.51B | Mid cap | +15.38% | Nov 2, 2026 |
| KLRA | Kailera Therapeutics, Inc. | $2.39B | Mid cap | −29.08% | Oct 29, 2026 |
| ALMR | Alamar Biosciences, Inc. | $2.36B | Mid cap | +54.91% | Nov 5, 2026 |
| COAG | Hemab Therapeutics Holdings, Inc. | $2.30B | Mid cap | +44.68% | Nov 16, 2026 |
| MLYS | Mineralys Therapeutics, Inc. | $2.28B | Mid cap | +70.22% | Nov 10, 2026 |
| NBTX | Nanobiotix S.A. | $2.26B | Mid cap | +394.99% | Sep 29, 2026 |
| CLOV | Clover Health Investments, Corp. | $2.26B | Mid cap | +57.99% | Nov 4, 2026 |
| ADUS | Addus HomeCare Corporation | $2.25B | Mid cap | +4.50% | Nov 2, 2026 |
| MESO | Mesoblast Limited | $2.23B | Mid cap | +4.47% | Aug 27, 2026 |
| XRAY | DENTSPLY SIRONA Inc. | $2.18B | Mid cap | −21.61% | Nov 5, 2026 |
| ZBIO | Zenas BioPharma, Inc. | $2.15B | Mid cap | +97.73% | Nov 12, 2026 |
| STOK | Stoke Therapeutics, Inc. | $2.14B | Mid cap | +71.45% | Nov 3, 2026 |
| ZYME | Zymeworks Inc. | $2.10B | Mid cap | +96.28% | Nov 5, 2026 |
| NVCR | NovoCure Limited | $2.08B | Mid cap | +50.21% | Oct 29, 2026 |
| GENB | Generate Biomedicines, Inc. | $2.07B | Mid cap | +27.59% | Nov 5, 2026 |
| SRPT | Sarepta Therapeutics, Inc. | $2.06B | Mid cap | +7.69% | Nov 4, 2026 |
| AGIO | Agios Pharmaceuticals, Inc. Common Stock | $2.03B | Mid cap | −13.45% | Oct 29, 2026 |
| CMPS | COMPASS Pathways plc | $2.02B | Mid cap | +209.53% | Nov 3, 2026 |
| ATRA | Atara Biotherapeutics, Inc. | $94.15M | Micro cap | −24.05% | Nov 12, 2026 |
| CVRX | CVRx, Inc. | $87.12M | Micro cap | −56.75% | Nov 5, 2026 |
| GOSS | Gossamer Bio, Inc. | $85.01M | Micro cap | −92.93% | Nov 4, 2026 |
| DH | Definitive Healthcare Corp. | $84.34M | Micro cap | −80.44% | Nov 5, 2026 |
| OM | Outset Medical, Inc. | $79.89M | Micro cap | −69.56% | Nov 9, 2026 |
| PLRX | Pliant Therapeutics, Inc. | $73.69M | Micro cap | −31.36% | Nov 5, 2026 |
| SPRO | Spero Therapeutics, Inc. | $71.05M | Micro cap | −38.38% | Nov 12, 2026 |
| PMVP | PMV Pharmaceuticals, Inc. | $70.03M | Micro cap | −7.75% | Nov 16, 2026 |
| MCRB | Seres Therapeutics, Inc. | $47.81M | Micro cap | −74.79% | Nov 4, 2026 |
| KPTI | Karyopharm Therapeutics Inc. Common Stock | $44.46M | Micro cap | −74.90% | Nov 3, 2026 |
| PETS | PetMed Express, Inc. | $38.81M | Micro cap | −43.35% | Nov 16, 2026 |
| KYNB | Kyntra Bio, Inc. | $32.82M | Micro cap | −22.66% | Nov 9, 2026 |
| QNCX | Quince Therapeutics, Inc. | $31.84M | Micro cap | +100.71% | Nov 12, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.